Peregrine Asset Advisers’s Vertex Pharmaceuticals VRTX Stock Holding History

Peregrine Asset Advisers’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$290K	Buy	583 +1	+0.2%	+$443	0.06%	176
2026 Q1	$260K	Buy	+582	New	+$271K	0.07%	166
2023 Q3	–	Sell	-14,326	Closed	-$5.04M	–	168
2023 Q2	$5.04M	Buy	+14,326	New	+$4.83M	3.87%	7
2022 Q3	–	Sell	-14,916	Closed	-$4.2M	–	87
2022 Q2	$4.2M	Buy	+14,916	New	+$3.99M	3.06%	11
2020 Q1	–	Sell	-2,000	Closed	-$438	–	156
2019 Q4	$438	Buy	+2,000	New	+$405K	0.1%	71
2018 Q4	–	Sell	-13,562	Closed	-$2.61M	–	126
2018 Q3	$2.61M	Buy	+13,562	New	+$2.41M	1.18%	28
2017 Q4	–	Sell	-28,349	Closed	-$4.31M	–	121
2017 Q3	$4.31M	Buy	+28,349	New	+$4.27M	2.27%	16

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Peregrine Asset Advisers's VRTX Position: Q2 2026 in Review

Peregrine Asset Advisers increased its Vertex Pharmaceuticals (VRTX) stake by 0.17% in Q2 2026, buying an estimated $443 and bringing the position to 583 shares worth $290K. The position accounts for 0.06% of the portfolio, ranked #176.

Peregrine Asset Advisers first reported a position in VRTX in Q3 2017 and has held it in 7 quarters since. The position peaked at $5.04M in Q2 2023. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Peregrine Asset Advisers held 583 shares of Vertex Pharmaceuticals worth $290K as of Q2 2026.
Peregrine Asset Advisers bought 1 Vertex Pharmaceuticals share in Q2 2026, an estimated $443.
Vertex Pharmaceuticals made up 0.06% of Peregrine Asset Advisers's portfolio in Q2 2026, its #176 holding.
Peregrine Asset Advisers first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 7 quarters since.
Peregrine Asset Advisers's Vertex Pharmaceuticals position peaked at $5.04M in Q2 2023.
1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Peregrine Asset Advisers's 13F filing for Q2 2026, filed 10 Aug 2026.